Tesamorelin

Evidence type

Review

Direct or closely related Tesamorelin evidence

Publication and key finding

Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.

Tesamorelin (Egrifta™) is a synthetic analogue of human growth hormone-releasing hormone (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone.

Drugs

Source

PMID 21668043 · 2011

Evidence type

Observational study

Direct or closely related Tesamorelin evidence

Publication and key finding

Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.

Once-daily short-term treatment with a GHRH(1-44) analog, tesamorelin, augments basal and pulsatile GH secretion.

The Journal of clinical endocrinology and metabolism

Source

PMID 20943777 · 2010

Evidence type

Review

Tesamorelin mechanism or target context

Publication and key finding

The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders.

Growth Hormone-Releasing Hormone (GHRH) and its analogs have gained significant attention for their therapeutic potential across various domains, including oncology, regenerative medicine, and metabolic disorders.

Reviews in endocrine & metabolic disorders

Source

PMID 39592529 · 2024

Evidence type

Observational study

Direct or closely related Tesamorelin evidence

Publication and key finding

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.

A clinically significant VAT reduction with tesamorelin was associated with improved liver enzymes among HIV-infected patients with abdominal obesity and elevated baseline transaminases.

AIDS (London, England)

Source

PMID 28832410 · 2017